Century Therapeutics, Inc. develops induced pluripotent stem cell (iPSC)-derived cell therapies for autoimmune diseases, including type 1 diabetes, and cancer. Its platform uses an iPSC cell foundry and Allo-Evasion™ immune-evasion engineering to create allogeneic beta islet, T cell and natural killer cell programs, including CNTY-813 for type 1 diabetes and CD19-targeted CAR-iT work such as CNTY-308.
Recurring company updates address preclinical data presentations, regulatory-pathway disclosures, financial results, investor presentations, board and committee changes, and collaboration economics tied to the company’s collaboration, option and license agreement with Bristol-Myers Squibb.
Century Therapeutics (IPSC) reported a narrower third-quarter 2026 net loss while advancing two cell-therapy programs toward planned clinical milestones.
Net loss was $23.453 million, versus $34.422 million a year earlier. Research and development expenses fell to $18.060 million from $22.526 million, while administrative expenses rose to $7.146 million from $6.835 million. Cash, cash equivalents and investments totaled $174.1 million at September 30, versus $117.1 million at year-end 2025; Century estimates funding into 1Q 2029.
Century expects a 4Q 2026 investigational new drug application for CNTY-813, its type 1 diabetes therapy, with initial human safety and early efficacy data anticipated in 2H 2027. New animal data showed sustained blood-glucose control. CNTY-308, its CD19-targeted immune-cell therapy, is anticipated to enter the clinic in 2026. Nine-month net loss was $79.648 million versus $9.591 million net income.
Century Therapeutics (NASDAQ: IPSC) will attend the 2026 Jefferies Global Healthcare Conference in London on November 18, 2026.
Those interested in a one-on-one meeting with the company’s team during the conference should contact their respective Jefferies representative.
Century Therapeutics (IPSC) presented nonclinical CNTY-813 data supporting advancement of its stem-cell-derived islet replacement therapy for type 1 diabetes.
In a study lasting over eleven months, CNTY-813 maintained blood glucose control in diabetic mice until graft removal. All treated diabetic mice achieved normal blood glucose. Five clinical-scale batches produced consistent final product profiles, and the 29-day manufacturing process exceeded purity criteria at every stage. Delivery through the liver portal vein resulted in engraftment in rats at one month. Clinical-scale islets remained functional after 96 hours of cold storage, normalizing blood glucose in mice within 30 days.
Century expects an Investigational New Drug application in Q4 2026, subject to completing remaining enabling studies. Initial human safety and early efficacy data are anticipated in the second half of 2027.
Century Therapeutics (IPSC) has appointed biotechnology executive Joseph Truitt to its Board of Directors.
Truitt is Chief Executive Officer and a director of iECURE, serves as Chairman of the Board of Larimar Therapeutics (LRMR), and sits on the Board of Code Biotherapeutics. He previously held senior leadership roles at BioSpecifics Technologies and Achillion Pharmaceuticals, both acquired by larger pharmaceutical companies.
The appointment comes as Century advances CNTY-813, an iPSC-derived islet replacement therapy for type 1 diabetes, toward an IND submission targeted for the fourth quarter of 2026 after an FDA pre-IND meeting that aligned on key development elements, and prepares CNTY-308, a CD19-targeted CAR-iT cell therapy for B-cell-mediated diseases, for anticipated clinic entry in 2026. Both candidates use the company’s Allo-Evasion™ 5.0 platform.
Century Therapeutics (NASDAQ: IPSC) reported second quarter 2026 results and development progress for its iPSC-derived cell therapy pipeline. The company completed a pre-IND meeting with the FDA for CNTY-813, its iPSC-derived islet replacement therapy for type 1 diabetes, gaining general alignment on the nonclinical package, Phase 1 manufacturing process and proposed Phase 1/2 trial design, keeping an IND filing on track for 4Q 2026 and initial clinical data expected in 2H 2027.
Century also plans to advance CNTY-308, a CD19-targeted CAR-iT cell therapy, into the clinic in 2026. Cash, cash equivalents and investments were $197.2 million as of June 30, 2026, providing runway into 1Q 2029. Q2 R&D and G&A expenses declined year over year, while the company recorded a Q2 net loss of $34.6 million and an accumulated deficit of $848.1 million.
Century Therapeutics (NASDAQ: IPSC) will present preclinical data on its iPSC-derived islet replacement therapy CNTY-813 at two major diabetes meetings in 2026.
Oral presentations are scheduled at EASD 2026 on October 2 in Milan and the Breakthrough T1D Clinical & Research Congress 2026 on October 9 in Philadelphia.
Century Therapeutics (NASDAQ: IPSC) reported new preclinical data for CNTY-813, an iPSC-derived islet replacement therapy for type 1 diabetes, at ADA 2026. In diabetic mice, CNTY-813 restored and maintained normoglycemia for over eight months and showed no tumorigenesis in more than 140 animals.
Allo-Evasion™ 5.0 edits preserved glucose control and enabled immune evasion in humanized mouse models without immunosuppression. Century has established a Phase 1 manufacturing process with consistent endocrine purity and targets a CNTY-813 IND submission in 4Q 2026 and initial clinical data in 2H 2027.
Century Therapeutics (NASDAQ: IPSC) reported first quarter 2026 results and pipeline progress. Cash, cash equivalents and marketable securities were $217.0 million on March 31, 2026, with a projected cash runway into Q1 2029. Net loss was $21.6 million.
CNTY‑813 remains on track for an IND in 4Q 2026 with initial clinical data expected in 2H 2027, while CNTY‑308 is expected to enter clinical testing in 2026. The company also completed a $135 million private placement in January 2026 and reduced R&D and G&A expenses year over year.
Century Therapeutics (NASDAQ: IPSC) will deliver an oral presentation at the American Diabetes Association 86th Scientific Sessions on June 8, 2026, highlighting CNTY-813, an iPSC-derived islet cell replacement therapy engineered with Allo-Evasion™ 5.0 for type 1 diabetes.
The company says CNTY-813 is on track for an IND submission in 4Q 2026. Presentation details: oral talk by Leonardo Velazco-Cruz, PhD, abstract/session number 1318-OR, 2:45–3:00 p.m. CT.
Century Therapeutics (NASDAQ: IPSC) reported full-year 2025 results and pipeline progress on March 12, 2026. Key news: CNTY-813 is in IND-enabling studies with an IND submission expected in 4Q 2026 and initial clinical data anticipated in 2H 2027. CNTY-308 is advancing toward clinical entry in 2026. The company completed an oversubscribed $135 million private placement and says cash runway is extended into 1Q 2029. 2025 financials: cash and investments of $117.1 million, collaboration revenue of $109.2 million, R&D $95.7 million, G&A $24.0 million, and net loss of $9.6 million.